Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
More
JAK Inhibitor Therapeutic Pipeline Strengthens as 50+ Pharma
The JAK inhibitor therapeutic pipeline is rapidly expanding, with over 55 drug candidates being developed by more than 50 companies worldwide. Recent clinical advancements include Phase III studies for atopic dermatitis and Phase II trials for rheumatoid arthritis and myelofibrosis. Promising emerging therapies like povorcitinib and CPL409116 are highlighted, showcasing diverse approaches to targeting autoimmune and inflammatory disorders.